Rivaroxaban in Patients with ACS: Does the Data Support its Routine Use? - C. Michael Gibson, MD

↳ This is a section part of Moment: CRT 2015 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$9.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Rivaroxaban in Patients with ACS: Does the Data Support its Routine Use? presented by C. Michael Gibson, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$9.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

Update in advances in ACS & AMI Management

Other Components in this Moment

Oral Thrombin Inhibitors for State of the Art Atrial Fibrillation: Is There a Winner? - C. Michael Gibson, MD

Dabigatran: Are There Any Concerns? - Neal S. Kleiman, MD

Can we Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? - D. Angiolillo, MD, PhD

Rivaroxaban in Patients with ACS: Does the Data Support its Routine Use? - C. Michael Gibson, MD

When Should Aspirin Be Dropped From Triple Therapy? - Samir Pancholy, MD

Inhibition and Modulation Factor IX Activity with a Novel Aptamer System during PCI - Rationale for the REGULATE Trial - A. Michael Lincoff, MD

Loading Simple Education